Epstein-Barr virus vector-mediated gene transfer into human B cells: Potential for antitumor vaccination

Gene Therapy

Volumn 13, Issue 2, 2006, Pages 150-162

  Hellebrand, E ^a,b   Mautner, J ^b   Reisbach, G ^a   Nimmerjahn, F ^b   Hallek, M ^c   Mocikat, R ^b   Hammerschmidt, W ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

B cells; B CLL; EBV vecor; Gene transfer; GM CSF

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS VECTOR;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL LINEAGE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; EPSTEIN BARR VIRUS; EX VIVO STUDY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HLA MATCHING; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTIGEN PRESENTATION; B-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; ENDOCYTOSIS; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE COLONY-STIMULATING FACTOR; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; TRANSDUCTION, GENETIC;

HUMAN HERPESVIRUS 4; SIMPLEXVIRUS;

EID: 29944439850     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302602     Document Type: Article

References (62)

1. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227-238.
2. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
3. Rieger R, Kipps TJ. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res 2003; 63: 4128-4135.
4. Kofler DM, Buning H, Mayr C, Bund D, Baumert J, Hallek M et al. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2004; 11: 1416-1424.
5. Anonymous. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon: International Agency for Research on Cancer (IARC), 1997.
6. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 1989; 340: 393-397.
7. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Res 2003; 63: 2982-2989.
8. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000; 19: 3080-3089.
9. Schepers A, Pich D, Hammerschmidt W. A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. Eur Mol Biol Org J 1993; 12: 3921-3929.
10. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA 1998; 95: 8245-8250.
11. Metcalf D, Burgess AW, Johnson GR, Nicola NA, Nice EC, DeLamarter J et al. In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: Comparison with purified native GM-CSF. J Cell Physiol 1986; 128: 421-431.
12. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
13. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
14. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22: 3188-3192.
15. Simons JW. Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer. Hinyokika Kiyo 1997; 43: 821-822.
16. Dranoff G, Soiffer R, Lynch T, Mihm M, Jung K, Kolesar K et al. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 1997; 8: 111-123.
17. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21: 3343-3350.
18. Mahvi DM, Sondel PM, Yang NS, Albertini MR, Schiller JH, Hank J et al. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther 1997; 8: 875-891.
19. Nemunaitis J, Sterman D, Jablons D, Smith II JW, Fox B, Maples P et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Nat Cancer Inst 2004; 96: 326-331.
20. Delecluse HJ, Pich D, Hilsendegen T, Baum C, Hammerschmidt W. A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci USA 1999; 96: 5188-5193.
21. Delecluse HJ, Hammerschmidt W. The genetic approach to the Epstein-Barr virus: From basic virology to gene therapy. Mol Pathol 2000; 53: 270-279.
22. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM et al. (eds.), Field's Virology. Philadelphia: Lippincott-Williams & Wilkins, 2001, pp. 2511-2573.
23. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998; 17: 1700-1709.
24. Dirmeier U, Hoffmann R, Kilger E, Schultheiss U, Briseño C, Gires O et al. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005; 24: 1711-1717.
25. KulwichitW, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998; 95: 11963-11968.
26. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990; 61: 1315-1327.
27. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831-840.
28. Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 1989; 86: 9558-9562.
29. Karasuyama H, Kudo A, Melchers F. The proteins encoded by the VpreB and lambda 5 pre-B cell-specific genes can associate with each other and with mu heavy chain. J Exp Med 1990; 172: 969-972.
30. Neuhierl B, Feederle R, Delecluse HJ. Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci USA 2002; 99: 15036-15041.
31. Sugden B, Mark W. Clonal transformation of adult human leukocytes by Epstein-Barr virus. J Virol 1977; 23: 503-508.
32. Klausner RD, Donaldson JG, Lippincott-Schwartz J. Brefeldin A: Insights into the control of membrane traffic and organelle structure. J Cell Biol 1992; 116: 1071-1080.
33. Takada K, Horinouchi K, Ono Y, Aya T, Osato T, Takahashi M et al. An Epstein-Barr virus-producer line Akata: Establishment of the cell line and analysis of viral DNA. Virus Genes 1991; 5: 147-156.
34. Goldblum N, Daefler S, Llana T, Ablashi D, Josephs S, Salahuddin Z. Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein-Barr virus. Dev Biol Stand 1990; 72: 309-313.
35. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989; 140: 323-334.
36. Nimmerjahn F, Kobelt D, Steinkasserer A, Menke A, Hobom G, Behrends U et al. Efficient generation and expansion of antigen-specific CD4+ T cells by recombinant influenza viruses. Eur J Immunol 2003; 33: 3331-3341.
37. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995; 182: 389-400.
38. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
39. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
40. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
41. Kreppel F, Kochanek S. Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol 2004; 78: 9-22.
42. Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors. Leuk Lymphoma 2004; 45: 897-904.
43. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917-2924.
44. Janssens W, Chuah MK, Naldini L, Follenzi A, Collen D, Saint-Remy JM et al. Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. Hum Gene Therapy 2003; 14: 263-276.
45. Bonamino M, Serafini M, D'Amico G, Gaipa G, Todisco E, Bernasconi S et al. Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lenti-vectors. Gene Therapy 2004; 11: 85-93.
46. Lizee G, Gonzales MI, Topalian SL. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum Gene Therapy 2004; 15: 393-404.
47. Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M et al. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol 1999; 73: 4678-4688.
48. Conese M, Auriche C, Ascenzioni F. Gene therapy progress and prospects: episomally maintained self-replicating systems. Gene Therapy 2004; 11: 1735-1741.
49. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141-13146.
50. Strehl J, Selmayr M, Kremer JP, Hultner L, Lindhofer H, Mocikat R. Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells. Int J Cancer 1999; 83: 113-120.
51. Selmayr M et al. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Therapy 1999; 6: 778-784.
52. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12: 571-575.
53. Levitsky HI et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858-3865.
54. Maeda A et al. Epstein-Barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins. J Hum Virol 2001; 4: 227-237.
55. Teramoto N et al. Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle. J Hum Virol 2000; 3: 125-136.
56. Wahl U et al. Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: Preclinical evaluation. Clin Cancer Res 2003; 9: 4240-4246.
57. Posfai G, Koob MD, Kirkpatrick HA, Blattner FR. Versatile insertion plasmids for targeted genome manipulations in bacteria: Isolation, deletion, and rescue of the pathogenicity island LEE of the Escherichia coli O157:H7 genome. J Bacteriol 1997; 179: 4426-4428.
58. O'Connor M, Peifer M, Bender W. Construction of large DNA segments in Escherichia coli. Science 1989; 244: 1307-1312.
59. Cherepanov PP,Wackernagel W. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 1995; 158: 9-14.
60. Hammerschmidt W, Sugden B. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 1988; 55: 427-433.
61. Schultheiss U et al. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J 2001; 20: 5678-5691.
62. Nimmerjahn F et al. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 2003; 33: 1250-1259.